File this beneath “Not a second far too shortly.”
Immediately after many years of back-and-forth deliberations, the U.S. Food items and Drug Administration has agreed to evaluation a uncommon condition drug developed by a compact company that prepared to shelve more do the job if the company did not take this extensive-sought move.
Exclusively, the Fda approved a new drug application from Stealth BioTherapeutics for a therapy to fight Barth syndrome, which brings about an enlarged heart, muscle weak spot, and a shortened daily life expectancy. The company also declared it would keep an advisory committee conference to review the software, but no date has been established. However, the Food and drug administration did not problem a precedence overview, which could delay acceptance.
Proceed to STAT+ to read through the full story…